HOME >> BIOLOGY >> NEWS
Report in Science on x-ray crystal structure of matrix Metalloproteinase-2 (MMP-2)

MMP-2 is a key target for anti-cancer drug development

Research Triangle Park, N.C.--June 4, 1999-- BioStratum Incorporated announced today the publication of a paper in the journal SCIENCE (volume 284, pages 1667-1670) reporting the three-dimensional structure of the matrix metalloproteinase-2 (MMP-2), a key molecular target for a number of anti-cancer drug candidates currently in clinical development. This work was completed by one of BioStratum's founding scientists, Dr. Karl Tryggvason of the Karolinska Institute, Stockholm, Sweden.

The elucidated structure of MMP-2 provides valuable information on the function and regulation of this important enzyme, and provides for the design of improved MMP-2 specific inhibitors for clinical evaluation. BioStratum owns intellectual property rights to this technology and to new and improved MMP-2 inhibitors that may be identified.

Matrix metalloproteinases (MMPs) are involved in tissue growth and wound repair. MMPs work by degrading substances in the extracellular matrix (the area outside of cells) thereby enabling the movement and expansion of cells, the deposition of new extracellular matrix, and the subsequent development of new tissue. MMP-2 acts directly on type IV collagen, a principal component of the basal lamina, a specialized form of the extracellular matrix. The activation of MMPs has been implicated in the invasive growth and spread of tumors. Several clinical studies are in progress evaluating the effectiveness of MMP inhibitors as anti-cancer agents, and many more are projected to enter clinical trials in the near future.

The elucidated molecular structure is the culmination of seven years of effort in Dr. Tryggvason?s laboratory. "This advance is providing important insights into the catalytic and regulatory mechanisms of this enzyme. It also provides an additional tool to aid in the design of improved MMP inhibitors to combat the spread of cancer," said Dr. Tryggvason.<
'"/>

Contact: J. Wesley Fox, Ph.D.
info@biostratum.com
919-572-6515
Noonan/Russo Communications
4-Jun-1999


Page: 1 2 3

Related biology news :

1. Report outlines vision and recommendations for microbiology in the 21st Century
2. Report outlines steps needed to lessen smallpox threat
3. Reporters from Science Magazine to receive ASM Public Communications Award
4. Report in BioScience details global decline of nonmarine mollusks
5. National Academies news: Report on EPAs particulate matter research
6. Report details growing climate change threat to coral reefs
7. Report to aid nation in managing freshwaters
8. Report examines use of antibiotics in agriculture
9. Report offers action plan for curbing diseases that kill millions
10. Report focuses on the science and safety of genetically modified crops
11. Report considers role of science in a world made vulnerable by terrorism

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/20/2017)... , March 20, 2017 PMD Healthcare ... personal spirometer and Wellness Management System (WMS), a remote, ... Founded in 2010, PMD Healthcare is a Medical Device, ... a mission dedicated to creating innovative solutions that empower ... With that intent focus, PMD developed the first ever ...
(Date:3/9/2017)... SAN FRANCISCO and MOUNTAIN VIEW, ... Zipongo , "Eating Well Made Simple," and 23andMe ... to help guide better food choices.  Zipongo can now ... only their food preferences, health goals and biometrics, but ... to certain food choices. Zipongo,s personalized food ...
(Date:3/2/2017)... 2017 Summary This report provides all ... partnering interests and activities since 2010. ... Read the full report: ... 2010 report provides an in-depth insight into the partnering activity ... On demand company reports are prepared upon purchase to ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... -- According to a report by Transparency Market Research ... to the presence of a large pool of participants; however, only ... and Sigma-Aldrich, compete with each other in this market. With Proliant ... 76% of this market in 2016.  ... As of now, a large number of vendors ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... monitoring solutions, today announced the hire of Dr. Sigmund “Sig” Floyd as Vice ... applications, strategic partnerships and joint development activities. , “Dr. Floyd’s career has spanned ...
(Date:3/22/2017)...  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical ... address significant unmet medical needs in rare diseases, ... ended December 31, 2016. "2016 ... we broadened our pipeline and pursued our vision ... with an initial focus on endocrinology," said ...
(Date:3/22/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ... ), a clinical-stage pharmaceutical company focused on ... today that Dr. Miriam Kidron , Oramed,s ... "Oral Insulin for Diabetes Treatment: Bypassing the Roadblock," ... Peptide Therapeutics (OPT) Boston Conference in Cambridge, ...
Breaking Biology Technology:
Cached News: